CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.
Joel Marcus, Alexandria Real Estate equities, talks about the immigration ban, and the benefits of tax repatriation from the biotech industry.
In an official statement, Mylan denies it illegally tried to prevent competition. CNBC's Meg Tirrell reports.
Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy & Outcomes director, discusses why the government should "nationalize" Gilead to help reduce the price of hepatitis C drugs.
The Fast Money traders discuss whether the pharmaceutical company will be acquired.
"Fast Money" trader David Seaburg pitches to the desk why to buy Eli Lilly.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
The “Fast Money” traders discusses whether Donald Trump is a risk to his own market rally, as he continues to target different sectors with criticism.
Michael King, JMP Securities senior analyst, weighs in on the biotech sector as President-elect Donald Trump puts the pharmaceutical industry in his cross hairs, calling it "disastrous."
CNBC's Bob Pisani takes a closer look at how the market's reaction to President-elect Donald Trump's first news conference since Election Day.
John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.
The “Fast Money” traders weigh in on biotech as the sector continues to boost the Nasdaq towards record highs.
Shire CEO Dr. Flemming Ornskov speaks to CNBC's Meg Tirrell about drug pricing for rare-disease drugs and his company's business strategy.
Allergan CEO Brent Saunders speaks to CNBC's Meg Tirrell about company expectations for 2017 and the future of biotech.
Valeant CEO Joseph Papa speaks to CNBC's Meg Tirrell about the company's turnaround process and drug price increases.
Monsanto CEO Hugh Grant discusses the deal between Bayer and Monsanto and what the upcoming Trump administration could mean for the company.
That leaves 220 workers to focus on Theranos' business plans.
Ronny Gal, Sanford C. Bernstein senior analyst, discusses his outlook for the biotech sector.
CNBC's Meg Tirrell discusses what to expect from the JPMorgan Health Care Conference 2017.
A judge ruling blocks Sanofi and partner Regeneron from selling their cholesterol drug, which is a victory for Amgen. CNBC's Meg Tirrell reports.